MARKET

BRNS

BRNS

Barinthus Biotherapeutics plc
NASDAQ
0.7213
+0.0003
+0.04%
After Hours: 0.7201 -0.0012 -0.17% 16:10 12/05 EST
OPEN
0.7392
PREV CLOSE
0.7210
HIGH
0.7480
LOW
0.7213
VOLUME
10.27K
TURNOVER
--
52 WEEK HIGH
2.920
52 WEEK LOW
0.6400
MARKET CAP
29.45M
P/E (TTM)
-0.3834
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BRNS last week (1124-1128)?
Weekly Report · 6d ago
Weekly Report: what happened at BRNS last week (1117-1121)?
Weekly Report · 11/24 10:12
Barinthus Biotherapeutics Price Target Raised to $4.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 11/17 12:39
Barinthus Biotherapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/17 12:39
HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Raises Price Target to $4
Benzinga · 11/17 12:29
Buy Rating for Barinthus Biotherapeutics: Promising Clinical Developments and Strategic Merger with Clywedog Therapeutics
TipRanks · 11/17 11:35
Barinthus Biotherapeutics price target raised to $4 from $3 at H.C. Wainwright
TipRanks · 11/17 11:20
Weekly Report: what happened at BRNS last week (1110-1114)?
Weekly Report · 11/17 10:11
More
About BRNS
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.

Webull offers Barinthus Biotherapeutics PLC - ADR stock information, including NASDAQ: BRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BRNS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BRNS stock methods without spending real money on the virtual paper trading platform.